Compound ID | 1820
Class: Beta-lactamase inhibitor (diazabicyclooctane [DBO])
| Spectrum of activity: | Gram-negative |
| Details of activity: | Inhibits PBP2 and is unaffected by β-lactamase mediated resistance. Active against Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii |
| Description: | Synthetic compound. Inhibitor of serine Beta-Lactamases |
| Institute where first reported: | Entasis Therapeutics |
| Year first mentioned: | 2021 |
| Highest developmental phase: | Preclinical |
| Development status: | Active (as of 2022) |
| Chemical structure(s): | |||||||||||
|
|
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/155920149 |
| Guide to Pharmacology: | ETX0462 |
| Citation: | https://www.nature.com/articles/s41586-021-03899-0 |